万维提示：
1、该刊只有国际刊号！
2、投稿方式：在线投稿。
3、官网网址：
https://onlinelibrary.wiley.com/journal/26882663
（微信公众号信息）
4、投稿系统：https://mc.manuscriptcentral.com/medcomm
5、主办单位官网：https://www.scimea.cn/
（四川省国际医学交流促进会）
6、官网邮箱：editorial@med-comm.org（编辑部）
medcomm@med-cens.org（编辑部）
7、出刊日期：月刊，每月出版1期。
8、官方微信公众号：四川省国际医学交流促进会（scimea）
2022年3月18日星期五
MedComm简介
MedComm 是由中国科学院院士魏于全教授亲自操刀的又一优秀生物医学期刊。魏院士2016年创办的一流学术期刊Signal Transduction and Targeted Therapy（简称STTT），2020年影响因子18.187，位于SCI期刊JCR分区Q1区，全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。我们有理由相信MedComm 潜力无限，未来可期，成为高水平的国际期刊。
MedComm 是2020年由世界顶级出版集团Wiley出版的生物医学英文期刊（https://onlinelibrary.wiley.com/journal/26882663），目前已被ESCI、DOAJ、BIOSIS Previews等知名数据库收录，大部分论文PubMed也已收录。MedComm 竭诚欢迎生物医学领域的科研工作者、医生、研究生积极投稿。
MedComm 编委团队由英国牛津大学James Henderson Naismith教授（英国皇家科学院院士、英国皇家爱丁堡科学院院士）、耶鲁大学Günter P. Wagner教授（美国国家科学院院士、美国科学促进会院士、美国艺术与科学院院士）、川大华西医院生物治疗国家重点实验室魏于全教授（中国科学院院士）领导。编委团队由全球10多个国家的著名科学家构成，其中超过20%为国内外院士，60%以上为国外专家，包括宋伟宏院士、蒋华良院士、彭勇、黄灿华以及何明亮教授等著名专家教授。
创刊至今，MedComm 始终坚持高水平、国际化、严标准的办刊策略，所有刊载内容均经过严格的同行评审，专业高效的编辑团队管理，得到了国内外同行学者的广泛认可。MedComm 收到来自全球范围内顶尖大学和研究机构的高水平稿件。目前已在线发表80余篇论文，包括Biomaterials 主编Kam. W. Leong院士、英属哥伦比亚大学宋伟宏院士、南阿拉巴马大学Gary A. Piazza教授、多伦多大学Masoud Mozafari教授、哈佛医学院Wenjun Deng教授、美国圣约翰大学的陈哲生教授、天津医科大学姚智、第三军医大学叶丽林、浙江大学王福俤等国内外多位院士与教授的文章。MedComm 由衷地感谢期刊作者、审稿人、编辑和读者的巨大贡献, MedComm 将再接再厉，发表更多高质量的论文，更好地服务于全球的读者和作者。
《MedComm》投稿指南
【官网信息】
Author Guidelines
1. SUBMISSION
Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/medcomm
Click here for more details on how to use ScholarOne.
Data protection:
By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Preprint policy:
Please find the Wiley preprint policy here.
This journal accepts article previously published on preprint servers.
MedComm will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.
For help with submissions, please contact: editorial@med-comm.org or medcomm@med-cens.org
2. AIMS AND SCOPE
MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance on human health. The journal emphasizes on original findings that advances the understanding of pathogenesis or improves the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged.
MedComm is interested in the topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology or artificial intelligence. Clinical and experimental advances that provide the disease characteristics, pathogenic mechanism or medical techniques are focused by the journal.
Topics of interest include, but are not limited to:
Epigenetics, genomics, proteomics and metabonomics
Non-coding RNA in disease
Cell senescence and cell death
Cellular signal transduction
Gene therapy and Gene editing
Cancer immunology and Immunotherapy
Structural Biology, chemical genomics and drug discovery
High-definition imaging
Artificial intelligence in medicine
Stem cells and Regenerative medicine
Nanomedicine and drug delivery system
Early disease diagnosis and biomarkers
Clinical trials evaluating new treatments for cancer or other diseases
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
Original article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make significant contribution to the scientific knowledge in biomedical areas. Typically, the research will provide insight into an as yet unknown mechanism or poorly understood process, constitute a highly significant contribution to our understanding of biomedicine, and be of general interest to the biomedicine community. Research article will typically be 6000 words in length, with up to 8 figures and tables in total, and no limitation on the number of references.
Review, including systematic reviews and meta-analyses, is typically written by leading experts in the filed within the journal’s scope. Reviews papers help specialists to keep up with the current state of knowledge in a specific research area and provide informative message for non-specialists. Reviews aim to be a critical and concise overview of the most recent advances in a specific research field. Reviews will typically be no limitation on words in length, with up to 8 figures and tables in total, and no limitation on the number of references.
Letter to the Editor provides the rapid and concise report of a novel discovery that is brief in nature and should be of general interest to the field of biomedicine. Letters will typically be 1200 words in length excluding, references, figures and tables, with up to 1 figures and tables in total, and no more than 10 references.
Highlights aims to point the MedComm readership to the latest novel findings published in other high-impact journals. Research Highlight should contain no more than 1200 words in length excluding, references, figures and tables, up to 10 references. and 1 display item.
Editorials are the most important statement and opinions of global opinion leaders in relevant specialties and specially invited by the Editor, but unsolicited material may be considered. Please approach the Editorial Office (editorial@med-comm.org or medcomm@med-cens.org) before submitting this material. Editorials have a limit of 1,000 words, with up to 2 figures and tables in total and no more than 5 references.
Perspectives discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance. Perspectives are typically 3000 words in length, with up to 4 figures and tables in total and no more than 70 references.
4. PREPARING THE SUBMISSION
Cover Letters
Cover letters are not mandatory; however, they may be supplied at the author’s discretion.
Parts of the Manuscript
The manuscript should be submitted in separate files: main text file; figures.
Main Text File
The text file should be presented in the following order:
A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
A short running title of less than 40 characters;
The full names of the authors;
The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
Acknowledgments;
Abstract and keywords;
Main text;
References;
Tables (each table complete with title and footnotes);
Figure legends;
Appendices (if relevant).
Figures and supporting information should be supplied as separate files.
For the benefit of the reviewers and editors, please include line numbers in your main text files.
Abstract
Please provide an abstract of 200 words containing the major keywords summarizing the article.
Keywords
Please provide three to six keywords.
Main Text
The journal uses British/US spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process.
Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/26882663/homepage/author-guidelines
